CA3177567A1 - Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent - Google Patents

Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Info

Publication number
CA3177567A1
CA3177567A1 CA3177567A CA3177567A CA3177567A1 CA 3177567 A1 CA3177567 A1 CA 3177567A1 CA 3177567 A CA3177567 A CA 3177567A CA 3177567 A CA3177567 A CA 3177567A CA 3177567 A1 CA3177567 A1 CA 3177567A1
Authority
CA
Canada
Prior art keywords
cells
culture
culture medium
stem cells
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177567A
Other languages
English (en)
French (fr)
Inventor
Yasutomo YANAGITA
Chugo RINOIE
Takefumi Ishidao
Itsunari Minami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Exosome Therapeutics Inc
Original Assignee
Cell Exosome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Exosome Therapeutics Inc filed Critical Cell Exosome Therapeutics Inc
Publication of CA3177567A1 publication Critical patent/CA3177567A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3177567A 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent Pending CA3177567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020063408 2020-03-31
JP2020-063408 2020-03-31
CA3173721A CA3173721A1 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3173721A Division CA3173721A1 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Publications (1)

Publication Number Publication Date
CA3177567A1 true CA3177567A1 (en) 2021-10-07

Family

ID=77930052

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3177567A Pending CA3177567A1 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
CA3173721A Pending CA3173721A1 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3173721A Pending CA3173721A1 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Country Status (8)

Country Link
US (1) US20230172992A1 (https=)
EP (2) EP4130240A4 (https=)
JP (3) JPWO2021200744A1 (https=)
CN (2) CN115362252A (https=)
AU (2) AU2021247879B2 (https=)
CA (2) CA3177567A1 (https=)
TW (2) TW202204605A (https=)
WO (1) WO2021200744A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021200744A1 (https=) * 2020-03-31 2021-10-07
EP4324914B1 (en) * 2021-06-11 2026-03-18 Fullstem Co., Ltd. Exosome production promoting agent and exosome production promoting method
JP7763475B2 (ja) * 2021-12-24 2025-11-04 株式会社日本バイオセラピー研究所 培養上清を生産する方法
WO2024019080A1 (ja) * 2022-07-19 2024-01-25 国立大学法人 長崎大学 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物
JP7851648B2 (ja) * 2022-12-23 2026-04-27 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 間葉系幹細胞又はその培養上清の利用
WO2025151805A1 (en) * 2024-01-10 2025-07-17 Biotech Therapeutics, LLC Mesenchymal stromal cell-derived extracellular vesicle-exosomes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
JPH05207875A (ja) * 1992-01-28 1993-08-20 Mitsui Toatsu Chem Inc 無血清培地
AU680909B2 (en) * 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
JPH10179147A (ja) * 1996-12-27 1998-07-07 Ishikawajima Harima Heavy Ind Co Ltd 植物細胞培養方法および二次代謝物高生産性植物細胞
EP1930413B1 (en) * 2005-08-23 2011-01-12 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
WO2010040262A1 (zh) * 2008-10-10 2010-04-15 深圳市嘉天源生物科技有限公司 分离动物胚胎间质性干细胞并提取其分泌物的方法
WO2012137970A1 (ja) 2011-04-08 2012-10-11 国立大学法人大阪大学 改変ラミニンおよびその利用
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN104884468B (zh) 2012-12-28 2018-08-31 国立大学法人大阪大学 附加有胶原结合性分子的改造层粘连蛋白及其利用
WO2014199754A1 (ja) * 2013-06-12 2014-12-18 国立大学法人大阪大学 ラミニンフラグメントが乾燥状態でコーティングされている細胞培養器具
CN106559994A (zh) * 2014-07-16 2017-04-05 国立大学法人大阪大学 层粘连蛋白片段的细胞培养基质活性增强方法
CN104651305A (zh) * 2015-02-13 2015-05-27 沈阳澔源生物科技有限公司 一种利用脐带间充质干细胞获取生物活性蛋白的方法
JP6849957B2 (ja) * 2015-11-10 2021-03-31 国立大学法人京都大学 ラミニンフラグメント含有培地を用いる細胞培養方法
RU2742828C2 (ru) * 2016-03-09 2021-02-11 Авита Интернэшнл Лтд. Применение стволовых клеток, экспрессирующих мезенхимальные и нейрональные маркеры, и их композиций для лечения неврологических заболеваний (варианты)
AU2018228352B2 (en) * 2017-02-28 2024-08-01 Centre Hospitalier Régional Universitaire De Nancy Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
JP6469287B1 (ja) * 2018-06-22 2019-02-13 株式会社 バイオミメティクスシンパシーズ 中空糸細胞培養装置，細胞培養方法，培養上清の製造方法
JPWO2021200744A1 (https=) * 2020-03-31 2021-10-07

Also Published As

Publication number Publication date
AU2021247879A1 (en) 2022-11-03
EP4155389A3 (en) 2023-07-12
JPWO2021200744A1 (https=) 2021-10-07
EP4130240A1 (en) 2023-02-08
EP4130240A4 (en) 2024-05-08
EP4155389A2 (en) 2023-03-29
CN116179480A (zh) 2023-05-30
TW202311526A (zh) 2023-03-16
AU2022259729B2 (en) 2025-05-01
AU2022259729A1 (en) 2022-12-01
AU2021247879B2 (en) 2025-04-24
JP2024015245A (ja) 2024-02-01
US20230172992A1 (en) 2023-06-08
JP2022181218A (ja) 2022-12-07
WO2021200744A1 (ja) 2021-10-07
TW202204605A (zh) 2022-02-01
CN115362252A (zh) 2022-11-18
CA3173721A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2022259729B2 (en) Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
Drobiova et al. Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications
Bicer et al. Impact of 3D cell culture on bone regeneration potential of mesenchymal stromal cells
Ren et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues
L. Maranda et al. Role of mesenchymal stem cells in dermal repair in burns and diabetic wounds
Sordi et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets
Vasalou et al. The effects of tissue healing factors in wound repair involving absorbable meshes: a narrative review
Choi et al. Mast cells, fibroblasts, and fibrosis: new clues to the riddle of mast cells
US20240294873A1 (en) Methods for the long-term expansion of granulocyte-macrophage progenitors and applications thereof
EP2294183A2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
KR20100035648A (ko) 체외 배양 및 증식 자기재생성 집락 형성 세포를 이용한 질환 및 장애 치료방법
CN110898078B (zh) 一种间充质干细胞分泌因子的制备及应用
JP2020072725A (ja) 向上された臍帯由来付着型幹細胞、その製造方法及びその用途
Kemaloğlu et al. The optimal effective dose of adipose-derived stem cell exosomes in wound healing
Montazersaheb et al. Mesenchymal stem cells and cancer stem cells: an overview of tumor-mesenchymal stem cell interaction for therapeutic interventions
US20240117301A1 (en) Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
US20130259837A1 (en) Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
Iwatake et al. Designer umbilical cord-stem cells induce alveolar wall regeneration in pulmonary disease models
NZ793106A (en) Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
JP6695795B2 (ja) 造血細胞の増殖ペプチドおよびその用途
HK40089499A (zh) 增殖细胞和细胞生产物的生产法、间充质干细胞群和干细胞培养上清及其生产法、治疗剂
HK40084736A (en) Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
Moore The hematopoietic system and hematopoiesis
Pamulang Upscale production of canine adipose-derived mesenchymal stem cell-derived exosomes for wound healing in vitro
WO2024195863A1 (ja) 間葉系幹細胞増殖促進剤、間葉系幹細胞用培地、間葉系幹細胞及び培養上清

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250131

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250528

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250627

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250627

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251216

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260114